SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic
kidney cancer that has not responded to previous therapy with interleukin-2. SU5416 may stop
the growth of kidney cancer by stopping blood flow to the tumor